FBXO22 is highly expressed in melanoma, which enhances VEGF-mediated angiogenesis by stabilizing HIF-1α and promotes tumor metastasis; clinical data show that FBXO22 is significantly upregulated in 74.3% of patients with malignant melanoma, and its expression level is negatively correlated with prognosis (100). Here, FBXO22 is linked to neoplasm.